newsfilter
← Latest News
GlobeNewswire·

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

  • Kuehn Law, PLLC is investigating Skye Bioscience, Inc. (NASDAQ: SKYE) officers & directors for potential fiduciary duty breaches.
  • A federal lawsuit alleges insiders misrepresented or failed to disclose that nimacimab was less effective than claimed.
  • The suit claims clinical, regulatory, & commercial prospects for nimacimab were overstated due to these misrepresentations.
  • Public statements regarding Skye Bioscience are alleged to have been materially false & misleading at all relevant times.
  • Shareholders who purchased SKYE prior to November 4, 2024, are encouraged to contact Justin Kuehn, Esq. for potential legal action.
  • Kuehn Law covers all case costs & charges no fees to investor clients.
  • The firm warns that there may be limited time to enforce shareholder rights.
  • Contact information for Kuehn Law, PLLC includes email justin@kuehn.law & phone (833) 672-0814.